e-learning
resources
Paris 2018
Wednesday, 19.09.2018
Eosinophils in airway disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Late Breaking Abstract - Protection by budesonide against clinically important deteriorations (CID) in patients with COPD is dependent on blood eosinophil counts (EOS)
M. Bafadhel (Oxford, United Kingdom), D. Sing (Manchester, United Kingdom), C. Jenkins (Sydney, Australia), S. Peterson (Lund, Sweden), T. Bengtsson (Lund, Sweden), M. Fagerås (Gothenburg, Sweden)
Source:
International Congress 2018 – Eosinophils in airway disease
Session:
Eosinophils in airway disease
Session type:
Oral Presentation
Number:
5381
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Bafadhel (Oxford, United Kingdom), D. Sing (Manchester, United Kingdom), C. Jenkins (Sydney, Australia), S. Peterson (Lund, Sweden), T. Bengtsson (Lund, Sweden), M. Fagerås (Gothenburg, Sweden). Late Breaking Abstract - Protection by budesonide against clinically important deteriorations (CID) in patients with COPD is dependent on blood eosinophil counts (EOS). 5381
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Late Breaking Abstract - Lack of stability of blood eosinophil counts in patients with COPD.
Source: International Congress 2019 – Blood eosinophils and more in airway diseases
Year: 2019
Late Breaking Abstract - Blood eosinophil count (EOS) can accurately predict responsiveness to inhaled corticosteroids (ICS) in COPD, but only if measured while patients are not receiving steroids.
Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS
Year: 2018
Late Breaking Abstract - The blood eosinophils count as a predictor of the response for omalizumab (OMA) in patients suffering from severe allergic asthma
Source: International Congress 2019 – Blood eosinophils and more in airway diseases
Year: 2019
Late Breaking Abstract - Blood eosinophil count and exacerbation history in COPD: pooled analysis of 24,103 patients
Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases
Year: 2019
Late Breaking Abstract - Blood eosinophil counts and treatment response in COPD: analyses of IMPACT
Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS
Year: 2018
Blood eosinophil (EOS) count, exacerbation rate and response to roflumilast in patients with severe COPD
Source: International Congress 2017 – What is new in COPD management and prognosis: findings from large studies?
Year: 2017
Minimal effect of inhaled corticosteroids (ICS) on blood eosinophil count in steroid-naïve COPD patients
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
Effect of indacaterol/glycopyrronium (IND/GLY) vs salmeterol/fluticasone (SFC) on moderate or severe COPD exacerbations and lung function based on baseline blood eosinophil counts: Results from the FLAME study
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016
Late Breaking Abstract - Benralizumab treatment strongly reduces blood basophils in patients with severe eosinophilic asthma
Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma
Year: 2019
Relationship of blood eosinophil count to exacerbations in asthma patients with a COPD diagnosis
Source: International Congress 2015 – Epidemiological studies of asthma and allergy
Year: 2015
Distribution of blood eosinophil in COPD patients
Source: International Congress 2014 – Lung function, COPD and inflammation
Year: 2014
Blood eosinophil count as a predictor of obstructive airway disease (OAD) in a high parasite burden setting
Source: International Congress 2016 – Exploring mechanisms in health and disease
Year: 2016
Late Breaking Abstract - Inhaled corticosteroids (ICS), blood eosinophils (EOS), and FEV1 decline in patients with Chronic Obstructive Pulmonary Disease in a large UK primary healthcare setting
Source: International Congress 2018 – Epidemiology of COPD : from exarcebations and comorbidities to asthma-COPD overlap syndrome (ACOS)
Year: 2018
Blood eosinophil guided prednisolone therapy for exacerbations of COPD: A further analysis
Source: International Congress 2014 – COPD exacerbations
Year: 2014
Relationship of blood eosinophil count to exacerbations in COPD
Source: International Congress 2016 – Airway response to infection
Year: 2016
Late Breaking Abstract - Association between blood eosinophils and exacerbation risk in COPD primary care
Source: International Congress 2017 – COPD: from screening to risk factors of lung cancer
Year: 2017
Effect of baseline eosinophil count on response to CYT003-QbG10 in patients with persistent allergic asthma
Source: Annual Congress 2013 –Studies of asthma in man
Year: 2013
Late Breaking Abstract - Anti-IL-5 mepolizumab minimally influences residual blood eosinophils in severe asthma
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021
LATE-BREAKING ABSTRACT: Exacerbation phenotype directed corticosteroid therapy of COPD: Value of blood eosinophilia (primary results)
Source: International Congress 2015 – The relevance of diagnostic and monitoring tools in clinical practice
Year: 2015
Exacerbations in the subpopulations and intermediate outcome measures in COPD study (SPIROMICS, NHLBI) are associated with sputum eosinophilia but not blood eosinophilia
Source: International Congress 2016 – What's new in biomarker analysis?
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept